Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. Available from: http://www.eurosurveillance.org / ViewArticle.aspx?ArticleId=21169


In this issue


Home Eurosurveillance Edition  2008: Volume 13/ Issue 2 Article 7
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 13, Issue 2, 10 January 2008
News
Unusual brain disease death in the United Kingdom: possible implications for variant Creutzfeldt-Jacob disease
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Editorial team. Unusual brain disease death in the United Kingdom: possible implications for variant Creutzfeldt-Jacob disease. Euro Surveill. 2008;13(2):pii=8013. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8013

 

A British woman who died of a brain disease with similarities to variant Creutzfeldt-Jacob disease (vCJD) in 2000 had a different genetic marker from all previous vCJD patients, according to researchers from the National Hospital for Neurology and Neurosurgery in the United Kingdom (UK) in a case report published in Archives of Neurology [1].

Cases of vCJD were first seen in the UK in 1996 following an epidemic of bovine spongiform encephalopathy (BSE) in cattle, sparking fears of a possible pandemic. The European Commission's Scientific Steering Committee - specially convened as a result of such fears - stated in 1999 that as many as 500,000 people could have been exposed to BSE from each single infected bovine, leading to speculation that millions of people could be at risk [2]. Such estimations have since appeared overly pessimistic; according to the European and Allied Countries Collaborative Study Group of CJD, 163 people have died of confirmed or probable vCJD in the UK to date [3].

Until the case described in this latest paper, all vCJD patients tested were homozygous for methionine (MM) at codon 129 of the prion protein gene (PRNP). This patient had the valine-homozygous (VV) form of the prion protein (PrP), that was previously believed to confer protection against vCJD.

The scrapie isoform of PrP (PrPSc) isolated from her brain tissue was similar to the molecular strain (PrPSc type 4) typical for vCJD, but showed an altered protease cleavage pattern in the presence of a metal chelator. This therefore raises the possibility of a new form of the disease. However, the article's authors stressed that such a conclusion cannot be drawn from one case alone.


References

  1. Mead S, Joiner S, Desbruslais M, Beck JA, O'Donoghue M, Lantos P, Wadsworth JD, Collinge J. Creutzfeldt-Jakob disease, prion protein gene codon 129VV, and a novel PrPSc type in a young British woman. Arch Neurol. 2007 Dec;64(12):1780-4.
  2. Opinion of the Scientific Steering Committee on the human exposure risk (HER) via food with respect to BSE. 10 December 1999. Available from: http://ec.europa.eu/food/fs/sc/ssc/out67_en.pdf
  3. The European And Allied Countries Collaborative Study Group Of CJD. Cases of vCJD worldwide. December 2007. Available from: http://www.eurocjd.ed.ac.uk/vcjdworldeuro.htm

 



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.